Funded Biotechnology Startups in Germany
The 50 most recent funding rounds in German biotechnology span from May 2023 through October 2025, with disclosed amounts ranging from $930K (Zendia, Nordr…
The 50 most recent funding rounds in German biotechnology span from May 2023 through October 2025, with disclosed amounts ranging from $930K (Zendia, Nordrhein-Westfalen) to $358M (Tubulis, Munich). Bayern and Berlin dominate by company count — Bayern hosts a cluster centered on Munich and Planegg, including Tubulis, ATAI Life Sciences, SciRhom, and Insempra, while Berlin accounts for Formo, Booster Therapeutics, Tacalyx, and Lucid Genomics, among others. Baden-Württemberg adds a third concentration, with immatics biotechnologies (Tübingen, $150M) and Impulse Dynamics (Stuttgart, $136M) among its larger disclosed rounds.
Stage distribution leans heavily toward "Series Unknown" — a label common in European public filings — alongside 12 Seed rounds and 3 Pre-Seed closes. Confirmed labeled later-stage deals include two Series C rounds, three Series B rounds, and four Series A rounds. Subsector spread is wide: oncology, genomics, mRNA delivery, precision psychiatry, and food fermentation biotech all appear within this set of 50.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds in this set?
Tubulis (Munich) led with a $358M Series C in October 2025, followed by immatics biotechnologies (Tübingen) at $150M in October 2024 and Impulse Dynamics (Stuttgart) at $136M in February 2024. SciRhom (Martinsried) raised $68M at Series A in July 2024, and both Infinite Roots (Hamburg, Series B) and Qualifyze (Frankfurt, Series B) closed at $58M and $54M respectively in late 2024.
Which cities and states have the most funded biotech companies here?
Bayern accounts for 12 of the 50 listings, concentrated in Munich and Planegg — the Planegg cluster alone includes ETHRIS, CPTx, Insempra, Bind-X, and mk2 Biotechnologies. Berlin follows with 11 companies across a range of stages and subsectors, from Pre-Seed (Lucid Genomics, Pacifico Biolabs) to later growth rounds (Formo at $36M, Booster Therapeutics at $15M Seed). Baden-Württemberg adds 9 companies spread across Tübingen, Ulm, Freiburg, Stuttgart, Konstanz, and Heilbronn.
How many of these rounds are from 2025?
Fourteen of the 50 entries carry a 2025 round date, with Tubulis ($358M, October 2025) and ATAI Life Sciences ($50M, July 2025) as the largest by disclosed amount. The 2025 deals span Munich, Berlin, Planegg, Rostock, Köln, Mainz, Halle an der Saale, Ulm, Freiburg, Jena, and Zwingenberg — indicating broad geographic distribution across the current year.
What subsectors show up most in this German biotech funding data?
Oncology and cancer immunotherapy appear repeatedly: immatics biotechnologies, TME Pharma, Tacalyx, and Eisbach Bio all operate in that space. Genomics and genetic tools are represented by Lucid Genomics, Akribion Genomics, and Detechgene. Food fermentation biotech forms a distinct cluster — Formo ($36M), Infinite Roots ($58M), and Cultimate Foods ($3M) all raised within this window, and precision psychiatry is visible through ATAI Life Sciences ($50M).
What does the early-stage deal size distribution look like for German biotech?
Among the 12 Seed rounds, disclosed amounts range from $970K (Aliform, Aachen) to $15M (Booster Therapeutics, Berlin), with Akribion Genomics ($8M), Tacalyx ($8M), Nuuron ($4M), and Detechgene ($4M) clustering in the $4M–$8M band. Several Seed deals — including SRTD Biotech, DeepEn, Viride, and eversyn — have undisclosed amounts. The 3 Pre-Seed rounds ranged from $900K (Aurora Life Science) to $3M (Pacifico Biolabs).
Are there any notable round type patterns beyond standard equity stages?
The dominant classification across this set is "Series Unknown," which accounts for roughly half the listings and spans a wide range — from $930K (Zendia) to $150M (immatics) — reflecting inconsistent disclosure practices in European biotech filings. One convertible note appears (Artcline, Rostock, $6M in September 2025), and one Series D is present (leon nanodrugs, München, undisclosed amount), making it the most advanced confirmed stage outside the two Series C rounds.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.